Home›Stock Screener›Vivimed Labs

Vivimed Labs Share Price Today | Stock Price & Vivimed Labs Share Screener

VIVIMEDLAB Pharmaceuticals & Biotechnology
Live Share Price NSE
₹7.63
▲ 0.32 (4.38%)
2026-04-15 00:00:00
Live Share Price BSE
₹5.50
▲ 0.00 (0.00%)
2026-11-17 00:00:00

As of April 15, 2026, the live Vivimed Labs share price (NSE: VIVIMEDLAB) is ₹7.63 on NSE and ₹5.50 on BSE, up 4.38% from the previous close, with shares trading between ₹7.35 and ₹7.67 in today's trading session, and a 52-week range of ₹5.28–₹26.60. Track VIVIMEDLAB market value to gauge the company's total market size. Use the Vivimed Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Vivimed Labs opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹18 and net income of ₹-147, with EBITDA of ₹-135, an operating margin of -1169.0% and a profit margin of -816.7%.

Vivimed Labs Market Cap ₹42.70 Cr.
VIVIMEDLAB P/E Ratio (TTM) -0.30
Vivimed Labs P/B Ratio -0.18
EPS (TTM) ₹-21.15
Dividend Yield -
Debt to Equity -
VIVIMEDLAB 52 Week High ₹26.60
Vivimed Labs 52 Week Low ₹5.28
Operating Margin -1169.00%
Profit Margin -816.67%
VIVIMEDLAB Revenue (TTM) ₹18.00
EBITDA ₹-135.00
Net Income ₹-147.00
Total Assets ₹754.00
Total Equity ₹-211.00

Vivimed Labs Share Price Chart

Track the current stock price of Vivimed Labs with an interactive chart. Analyse VIVIMEDLAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Vivimed Labs stock quote in one place.

The quote of ₹7.63 sits between the 52-week low of ₹5.28 and the 52-week high of ₹26.60, and the latest session moved 4.38% from the previous close.

Vivimed Labs Company Profile - Fundamental Screener

Screen Vivimed Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VIVIMEDLAB shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE526G01021.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE526G01021

Vivimed Labs Balance Sheet Screener

Screen VIVIMEDLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹754, down from ₹921 in 2025.

Latest statistics put total assets at ₹754 and shareholder funds at ₹-211.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 754 921 951 995 1,266 1,289 2,210 2,329 2,394 2,062
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 403 408 418 436 520 502 1,045 965 1,035 879

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 516 548 546 532 528 517 605 496 365 510
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity -211 -35 -6 39 364 432 835 944 1,239 734
Share Capital 17 17 17 17 17 17 17 17 17 16
Reserves & Surplus -227 -52 -22 23 348 415 493 602 885 718

Vivimed Labs Income Statement Screener - Profit & Revenue Analysis

Screen Vivimed Labs income statement and profit fundamentals. Analyze VIVIMEDLAB quarterly results. Vivimed Labs reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹18 and net profit was ₹-147, equal to earnings per unit of ₹-17.24, at an operating margin of -1169%.

In that period expenses were ₹152, interest cost ₹1 and tax ₹0. The next period listed, 2025-Dec, shows revenue of ₹16 and net profit of ₹-17.

Item 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec 2022-Sept

Revenue and Expenses

Revenue 18 16 21 22 30 37 25 29 46 42 36 36 38 56 44
Expenses 152 27 22 22 28 36 25 40 67 40 40 36 201 61 54

Operating Costs and Margins

EBITDA -135 -11 -1 0 2 1 -1 -11 -21 1 -4 0 -164 -5 -9
Operating Profit % -1169.00% -68.00% -5.00% -1.00% -10.00% 3.00% -3.00% -37.00% -74.00% 3.00% -18.00% -1.00% -444.00% -9.00% -21.00%
Depreciation 12 5 5 5 6 7 4 4 6 5 5 5 96 4 4
Interest 1 1 2 1 2 1 0 0 -33 13 12 11 9 9 9

Profit and Earnings

Profit Before Tax -147 -17 -7 -6 -6 -6 -5 -15 7 -17 -20 -16 -268 -18 -22
Tax 0 0 0 0 0 0 0 0 1 -1 0 0 -2 0 0
Net Profit -147 -17 -7 -6 -6 -6 -5 -15 5 -16 -20 -16 -266 -18 -22
EPS -17.24 -2.00 -0.88 -0.66 -0.68 -0.72 -0.62 -1.84 0.63 -1.94 -2.40 -1.88 -32.08 -2.20 -2.66

Vivimed Labs Cash Flow Screener - Liquidity Fundamentals

Screen VIVIMEDLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities used ₹2, and net cash flow was an outflow of ₹1.

Over the same period, investing activities used ₹5 and financing activities provided ₹5.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March

Cash from Operations and Investing

Operating Activities -2 -24 35 28 567 80 422 21 58 154
Investing Activities -5 28 -5 -16 404 -196 -89 -164 -69 -190

Financing and Net Cash

Financing Activities 5 -6 -34 -10 -1,015 72 -338 186 35 41
Net Cash Flow -1 -2 -3 1 -44 -44 -5 44 25 4

Vivimed Labs Shareholding Pattern Screener

See Vivimed Labs shareholding pattern with promoter, FII, and DII holdings. Check Vivimed Labs promoter holding and ownership changes for VIVIMEDLAB on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 7.57%, foreign institutions 1.64%, domestic institutions 0.00% and the public 68.75%, spread across 47,492 shareholders.

The shareholder count was 47,492 in 2026-Mar, compared with 48,957 in 2025-Mar.

Item 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept

Promoter Holding

Promoter Holding 7.57% 20.94% 7.77% 7.77% 7.77% 20.94% 20.94% 20.94%

Institutional Investors

FII Holding 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12%
Public Holding 68.75% 57.91% 65.19% 65.18% 65.06% 57.24% 57.23% 57.23%
Other Holding 21.91% 19.39% 25.29% 25.30% 25.41% 20.07% 20.07% 20.07%
Shareholder Count 47,492 48,957 48,928 48,925 49,221 49,016 49,012 49,003

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Vivimed Labs. Vivimed Labs dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹0.00 0.00%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.40 1.71%
2017-March ₹0.40 0.56%

Vivimed Labs Stock Index Membership - Nifty & Sensex

See which indices include Vivimed Labs stock. Check VIVIMEDLAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Vivimed Labs is not part of any tracked indices.
Only major market indices are tracked in our system.

Vivimed Labs Market Events Screener - Corporate Actions

Get Vivimed Labs corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Vivimed Labs stock events that may affect VIVIMEDLAB share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated July 17, 2026, with a record date of July 17, 2026.

It is followed by Quarterly Result Announcement dated May 30, 2026 and Quarterly Result Announcement dated March 13, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-07-17 2026-07-17 Quarterly Result Announcement NA -5.23%
2026-05-30 2026-05-30 Quarterly Result Announcement NA 0.15%
2026-03-13 2026-03-13 Quarterly Result Announcement NA -24.97%
2025-12-10 2025-12-10 Extraordinary General Meeting NA 0.00%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 0.00%
2025-09-30 2025-09-30 Annual General Meeting NA 0.00%
2025-08-13 2025-08-13 Quarterly Result Announcement NA 0.00%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 0.00%
2025-02-14 2025-02-14 Quarterly Result Announcement NA 0.00%
2025-01-10 2025-01-10 Quarterly Result Announcement NA 0.00%
2025-01-03 2025-01-03 Annual General Meeting NA 0.00%
2024-11-14 2024-11-14 Quarterly Result Announcement NA 0.00%
2024-08-14 2024-08-14 Extraordinary General Meeting NA 0.00%
2023-03-27 2023-03-27 Annual General Meeting NA -26.11%
2023-02-17 2023-02-17 Annual General Meeting NA -13.09%

Vivimed Labs Competitors Screener - Peer Stocks Comparison

Screen VIVIMEDLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Vivimed Labs Company Announcements - News & Reports Screener

Screen VIVIMEDLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated September 26, 2026.

The next most recent announcements are dated September 26, 2026 and September 23, 2026.

Date Update Actions
2026-09-26 Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors -
2026-09-26 Seeking Time For Holding AGM -
2026-09-23 Closure of Trading Window -
2026-09-08 Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors -
2026-08-17 Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors -
2026-07-22 Re- Lodgement Of Transfer Requests -
2026-07-22 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-17 Results As On 31.3.2026 -
2026-07-14 Board Meeting Intimation for Quarter & Year End Results 31.3.2026 -
2026-07-10 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-06-30 Closure of Trading Window -
2026-06-17 Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP) -
2026-05-30 Board Meeting Postponed -
2026-05-26 Update on board meeting -
2026-05-19 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-17 Board Meeting Intimation for Audited Results -
2026-04-23 Corporate Insolvency Resolution Process (CIRP)-Public Announcement -
2026-04-17 Admission To CIRP -
2026-04-08 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-04-06 Initial Disclosure -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹7.63, within a 52-week range of ₹5.28 to ₹26.60. The P/E ratio is -0.30 and the P/B ratio is -0.18, with earnings per unit of ₹-21.15. Market capitalisation stands at ₹42.70 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.